In the pathogenesis of rheumatoid arthritis (RA) B lymphocyte subpopulations are thought to be partly responsible for the disturbed immunoregulation.' CD 21, CD 22 Correspondence to Dr Sabine Hildebrandt, Division of Rheumatic Diseases, University of Connecticut, Farmington, CT, USA. peripheral blood should decrease during B cell activation, while CD 21 positive cells should increase. Studies on the MER showed that peripheral mononuclear cells (PMC) of patients with active disease expressed significantly less MER than those of patients with inactive RA, patients with other forms of rheumatic disease, or healthy controls."i 12 The object of this study was to investigate the expression of CD 21 in regard to disease activity and the relation between CD 21 and MER. In addition, we examined the possible biasing effects of drug treatment and production of the classical rheumatoid factor on the expression of B cell antigens.
Patients and methods

PATI ENTS
The study population consisted of 61 patients (18 Patients with inactive or moderately active disease had significantly more B cells than patients with active disease or control patients (moderately active RA:median=10-2%; inactive RA:median=10-5%; active RA:median=8-5%; control group:median =8%; Fig. 1 ).
Patients with inactive and moderately active RA showed significantly more MER/CD 22 than patients with active RA. In contrast with previous studies11 12 there was no significant difference between RA and control (control:median=32%; moderately active RA:median=44%; inactive RA:median=43%; active RA:median=23%; Fig.   2 ). There was a significant difference within the RA group for the CD 21/CD 22 subpopulation, but not in comparison with the control. Patients with active RA showed significantly more CD 21/CD22 cells than patients with inactive disease (active RA: median=77%; inactive RA:median=59%; Fig. 3 ).
DRUG TREATMENT
There were three different treatment schemes with a sufficient number of patients for statistical analysis: patients receiving azathioprine plus steroids or methotrexate plus steroids (n=5), patients receiving gold alone or gold plus NSAIDs (n=23), and patients receiving NSAIDs alone (n=4). These groups showed no difference in the expression of CD 22 or the MER and were equally represented in all groups of disease activity. Patients receiving NSAIDs had significantly more CD 21/CD 22 cells in the peripheral blood (median=83%) than patients receiving gold or gold plus NSAIDs 
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group.bmj.com on November 7, 2017 -Published by http://ard.bmj.com/ Downloaded from (median=62%) or patients receiving methotrexate or azathioprine plus steroids (median=59%; Fig. 4 ).
CLASSICAL RHEUMATOID FACTOR
Patients with seronegative RA receiving gold alone or gold and NSAIDs showed significantly more MER/CD 22 cells in the peripheral blood (median= 46%) than seropositive patients (median=33%) or control patients (median=32%; Fig. 5 (Fig. 6) .
To exclude the possibility that the relation between B cell subsets and disease activity may be explained by biasing factors we studied the relation between B cell subpopulations and drug treatment or the presence of classical rheumatoid factor. There group.bmj.com on November 7, 2017 -Published by http://ard.bmj.com/ Downloaded from was no relation between drug treatment and total B cell population, while the CD 21 positive cell fraction was significantly greater in patients with RA receiving NSAIDs than in patients receiving different drugs. Surprisingly we found that patients with seronegative RA had significantly more MER positive cells in the peripheral blood than patients with seropositive RA or control patients, but this only applied to patients receiving gold treatment. Nevertheless, these relations could not explain the connection between disease activity and B cell subsets as drug treatment and production of rheumatoid factor were equally distributed through all groups of disease activity.
Olsen and Jasin investigated in a retrospective study the pokeweed mitogen induced IgM and IgM rheumatoid factor production in PMC of patients with RA receiving gold treatment. 
